FindTrial
Sign In

Placebo 5mg

DRUG2 trials

Sponsors

Medical University of Graz, Vigonvita Life Sciences

Conditions

Cardiac Resynchronization TherapyErectile DysfunctionHeart Failure With Mid Range Ejection FractionHeart Failure With Reduced Ejection FractionImplantable Cardioverter-Defibrillators

Phase 2

Pharmacodynamic Study of TPN171H Tablets in Patients With Mild to Moderate Erectile Dysfunction
CompletedNCT05388825
Vigonvita Life SciencesErectile Dysfunction
Start: 2022-08-01End: 2023-02-17Updated: 2023-02-23

Phase 3

Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study
TerminatedNCT04600921
Medical University of GrazCardiac Resynchronization Therapy, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Reduced Ejection Fraction +1
Start: 2021-06-24End: 2023-10-18Updated: 2025-06-03

Related Papers

Ertugliflozin to Reduce Arrhythmic Burden in Patients with ICDs/CRT-Ds
NEJM Evidence2024-09-0112 citations
Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) – A phase III study
American Heart Journal2022-01-1632 citations